ELAN VS APLS Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

ELAN
10/100

ELAN returned -9.80% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

APLS
10/100

APLS returned 3.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ELAN
64/100

11 analysts offer 12-month price targets for ELAN. Together, they have an average target of 27, the most optimistic target put ELAN at 37 within 12-months and the most pessimistic has ELAN at 18.

APLS
83/100

3 analysts offer 12-month price targets for APLS. Together, they have an average target of 75.92, the most optimistic target put APLS at 113 within 12-months and the most pessimistic has APLS at 52.

Technicals

ELAN
89/100

ELAN receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

APLS
71/100

APLS receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

Earnings

ELAN
100/100

ELAN has missed earnings 1 times in the last 20 quarters.

APLS
10/100

APLS has missed earnings 14 times in the last 20 quarters.

Profit

ELAN
22/100

Out of the last 20 quarters, ELAN has had 6 profitable quarters and has increased their profits year over year on 2 of them.

APLS
10/100

Out of the last 20 quarters, APLS has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

ELAN
45/100

ELAN has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

APLS
54/100

APLS has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Elanco Animal Health Incorporated Common Stock Summary

New York Stock Exchange / ELAN
Healthcare
Drug Manufacturers - Specialty & Generic
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Apellis Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / APLS
Healthcare
Biotechnology
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.